PDCD1 and neoplasm: Additionally, the therapeutic potency of the new PD-1 targeting antibody, Sindilizumab, was evaluated in tumor-bearing mice and inhibited the PD-L1 positive tumor successfully, particularly the PD-L1 knockout tumor.